NCT03341429View on ClinicalTrials.gov

Evaluation of Liraglutide 3.0mg in Patients With Poor Weight-loss and a Suboptimal Glucagon-like Peptide-1 Response

PHASE4CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

August 22, 2018

Primary Completion Date

November 28, 2019

Study Completion Date

June 11, 2020

Conditions
Obesity
Interventions
DRUG

Liraglutide Pen Injector [Saxenda]

Daily injection of GLP-1 agonist (liraglutide 3.0 mg) for obese patients presenting poor weight loss (\<20%) after bariatric surgery and suboptimal GLP-1 levels.

DRUG

Placebo

Daily subcutaneous injection

Trial Locations (1)

NW1 2BU

UCLH, London

All Listed Sponsors
lead

University College, London

OTHER

NCT03341429 - Evaluation of Liraglutide 3.0mg in Patients With Poor Weight-loss and a Suboptimal Glucagon-like Peptide-1 Response | Biotech Hunter | Biotech Hunter